Celldex Therapeutics
CLDX
85 hedge funds and large institutions have $11.3M invested in Celldex Therapeutics in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 27 reducing their positions, and 20 closing their positions.
0.02% more ownership
Funds ownership: 1.97% → 1.99% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11% less funds holding
Funds holding: 95 → 85 (-10)
22% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 27
50% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 20
51% less capital invested
Capital invested by funds: $23.2M → $11.3M (-$11.9M)
Top Buyers
Top Sellers
CLDX Hedge Fund Activity: Q4 2018 in Review
85 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2018, worth a combined $11.3M — down 51% from $23.2M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CLDX and 10 opened new positions — a net loss of 10 holders — while 27 trimmed existing stakes and 21 added.
The largest buyer was Renaissance Technologies, adding an estimated $424K. The largest seller was BlackRock, cutting an estimated $633K.
- 85 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2018, down from 95 in Q3 2018.
- Funds reported $11.3M of Celldex Therapeutics stock for Q4 2018, down 51% quarter-over-quarter.
- 10 funds opened new Celldex Therapeutics positions in Q4 2018 and 20 closed out, a net change of -10 holders.
- The largest Celldex Therapeutics buyer in Q4 2018 was Renaissance Technologies, an estimated $424K added.
- The largest Celldex Therapeutics seller in Q4 2018 was BlackRock, an estimated $633K sold.
Based on aggregated 13F filings for Q4 2018.